A5016248743- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Respiratory viral infections research
- Immunodeficiency and Autoimmune Disorders
- Virology and Viral Diseases
- Pneumocystis jirovecii pneumonia detection and treatment
- Influenza Virus Research Studies
- Abdominal Trauma and Injuries
- Monoclonal and Polyclonal Antibodies Research
- Legionella and Acanthamoeba research
- Vector-borne infectious diseases
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Vectors
- Water Treatment and Disinfection
- Immune Cell Function and Interaction
- Streptococcal Infections and Treatments
- Antimicrobial Resistance in Staphylococcus
- Air Quality and Health Impacts
- COVID-19 Clinical Research Studies
- Immune Response and Inflammation
- Infective Endocarditis Diagnosis and Management
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Indoor Air Quality and Microbial Exposure
- Vaccine Coverage and Hesitancy
- Pancreatitis Pathology and Treatment
Norwegian Institute of Public Health
2015-2024
University of Oslo
1994-2015
Akershus University Hospital
2015
Oslo University Hospital
2004-2011
Østfold Hospital Trust
2009
Borregaard (Norway)
2008-2009
Norwegian Defence Research Establishment
2008
Norwegian Armed Forces
2007
University of Auckland
2007
Institute of Environmental Science and Research
2007
Perfluoroalkyl substances (PFAS) are suggested to have immunosuppressive effects; exposure in utero and the first years of life is special concern as fetuses small children highly vulnerable toxicant exposure. The objective this study was investigate effect pre-natal PFAS on responses pediatric vaccines immune-related health outcomes up 3 age. In prospective birth-cohort BraMat, a sub-cohort Norwegian Mother Child Cohort Study (MoBa), pregnant women from Oslo Akershus, Norway, were recruited...
On 21 May 2005, the Norwegian health authorities were alerted by officials from a local hospital that several recent patients had received diagnosis of legionnaires disease; all resided in 2 neighboring municipalities. We investigated outbreak to identify source and implement control measures.We interviewed surviving case harvested samples 23 businesses with cooling towers other potential infection sources. The locations patients' residences movements mapped. calculated attack rates risk...
ABSTRACT In July 2006, the seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in Norway with a reduced (2 doses + 1 boost) dose schedule. Post-PCV7 shifts reservoirs were assessed by two point prevalence studies of nasopharyngeal colonization among children day care centers, before (2006) and after (2008) widespread use PCV7. Nasopharyngeal swabs obtained from 1,213 children, 611 2006 602 2008. A total 1,102 isolates recovered. Serotyping, multilocus sequence typing,...
ABSTRACT There is currently no standardized serum bactericidal antibody (SBA) assay for evaluating immune responses to meningococcal outer membrane vesicle or protein vaccines. Four laboratories, Manchester Health Protection Agency (MC HPA), New Zealand Institute of Environmental Science and Research Limited (NZ ESR), Norwegian Public (NIPH), Chiron Vaccines (Chiron), measured SBA titers in the same panel human sera ( n = 76) from laboratory staff 21) vaccinated with MenBvac. Blood samples...
ABSTRACT Chronic HIV infection is characterized by chronic immune activation and dysfunctional T cells with elevated intracellular cyclic AMP (cAMP), which inhibits the cell capability. cAMP may be induced prostaglandin E 2 following lipopolysaccharide (LPS)-induced upregulation of cyclooxygenase type (COX-2) in monocytes due to LPS levels patients infection. This hypothesis was tested using celecoxib, a COX-2 inhibitor, for 12 weeks HIV-infected without antiretroviral treatment prospective,...
Abstract Background Streptococcus pneumoniae carriage is often asymptomatic but can cause invasive pneumococcal disease. Pneumococcal a prerequisite for disease, with children as main reservoir and transmitters. Childhood therefore be used to determine which serotypes circulate in the population may disease non-vaccinated population. In 2006, conjugate vaccine (PCV7) was introduced into Norwegian Immunisation Programme, replaced by more valent PCV13 2011. We investigated changes prevalence 4...
Biological treatment plants are frequently used to degrade organic substances in wastewater from wood refinement processes. Aeration ponds such provide an optimal growth environment for many microorganisms, including Legionella species. To investigate whether legionellae could be dispersed as aerosols the and transported by wind, wetted-wall cyclone SASS 2000PLUS impactors MAS-100 STA-204 were collect air samples directly above, upwind, downwind of aeration during a 4-month period....
Shifts in the pneumococcal population colonizing healthy children are expected after switching from a 7-valent conjugate vaccine (PCV7) to 13-valent (PCV13) childhood immunization program. We assessed effects of switch by comparing carriage and serotype genetic diversity pneumococci carried PCV13-era with those prevaccination-era PCV7-era.Nasopharyngeal swabs were obtained autumn 2013 attending day-care centers (874 swabs, 583 isolates). Serotyping, multilocus sequence typing antimicrobial...
3Biochemical Pharmacology, University of Konstanz, P.O. Box M 655, 78457 Germany; 4National Institute Public Health (NIPH), Department Vaccinology, 4404 Torshov, Geitmyrsveien 75, 0403 Oslo, Norway; 5Milenia-Biotec, Hohe Strasse 4–8, 61231 Bad Nauheim, 6Medical Products Agency, 26, Husargatan 8, 751 03 Uppsala, Sweden; 7European Directorate for the Quality Medicines, Council Europe, 907, 67029 Strasbourg Cedex 1, France; 8ECVAM, JRC and Consumer Protection, European Commission, 21020 Ispra...
The antimicrobial effect of soluble beta-1,3-D-glucan from Sclerotinia sclerotiorum (SSG) was examined in mice experimentally infected intraperitoneally (i.p.) with Streptococcus pneumoniae serotypes 4 and 6B. SSG administered i.p. either 3 days before challenge or 3-48 h after challenge. number bacteria blood samples the mouse survival rates were recorded. Pre-challenge administration protected dose-dependently against both S. type 6B infections. injected 24 post-challenge had a curative...
MenBvac and MeNZB are safe efficacious vaccines against serogroup B meningococcal disease. is prepared from a B:15:P1.7,16 strain (strain 44/76), B:4:P1.7-2,4 NZ98/254). At 6-week intervals, healthy adults received three doses of (25 microg), or the (doses 12.5 microg each vaccine) combined, followed by booster 1 year later. Two-thirds subjects who monovalent vaccine in primary schedule other as dose. The immune responses to combined were same magnitude homologous individual observed. 6...
ABSTRACT To investigate the epidemiological patterns and genetic characteristics of disease caused by group A Streptococcus (GAS), all available isolates from invasive cases in Norway during 2006 to 2007 (262 isolates) were subjected antimicrobial susceptibility testing, T serotyping, emm typing, multilocus sequence typing screened for known streptococcal pyrogenic exotoxin (Spe) genes, smeZ , ssa . The average incidence rate was 3.1 per 100,000 individuals. most prevalent types (STs) STs...
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian Childhood Immunization Program in 2006. A substantial effectiveness of PCV7 immunization against invasive disease has been demonstrated, whereas evidence its impact on respiratory tract infections are less consistent.This study included children participating Mother and Child Cohort Study, which recruited pregnant women between 1999 2008. Maternal report acute otitis media (AOM), lower (LRTIs) asthma child...